Effectiveness of Cannabis in the Treatment of Tinnitus Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01969474 |
Recruitment Status
:
Withdrawn
First Posted
: October 25, 2013
Last Update Posted
: December 28, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Tinnitus | Drug: Cannabis Drug: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Phase 1 Study to Study the Efficacy and Safety of Cannabis in the Treatment of Tinnitus |
Study Start Date : | December 2013 |
Estimated Primary Completion Date : | December 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Cannabis
Treatment with a Cannabis capsule
|
Drug: Cannabis
Cannabis capsules given once daily for a month
|
Placebo Comparator: Placebo
Placebo
|
Drug: Placebo
Placebo
|
- Tinnitus handicap inventory score [ Time Frame: 2 months ]Patients will be monitored during a month (treatment time) and a month later

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Tinnitus lasting more than 3 months
- Tinnitus Handicap Inventory score over 58
- Treated previously for tinnitus (2 modalities)
Exclusion Criteria:
- Prior use of drugs
- Current use of Cannabis
- Neurologic or Psychiatric disease
- Heart Failure
- Ischemic Heart Disease
- Immune Deficiency
- Acoustic Neuroma

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01969474
Israel | |
Wolfson Medical Centre | |
Holon, Israel |
Responsible Party: | Oron Yahav, MD, Wolfson Medical Center |
ClinicalTrials.gov Identifier: | NCT01969474 History of Changes |
Other Study ID Numbers: |
1.01 |
First Posted: | October 25, 2013 Key Record Dates |
Last Update Posted: | December 28, 2016 |
Last Verified: | December 2016 |
Keywords provided by Oron Yahav, Wolfson Medical Center:
Tinnitus Cannabis |
Additional relevant MeSH terms:
Tinnitus Marijuana Abuse Hearing Disorders Ear Diseases Otorhinolaryngologic Diseases Sensation Disorders |
Neurologic Manifestations Nervous System Diseases Signs and Symptoms Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |